Aileron Therapeutics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
James Windsor
Chief executive officer
US$715.9k
Total compensation
| CEO salary percentage | 11.9% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.04% |
| Management average tenure | no data |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky
Aug 18
Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?
Dec 30Aileron Therapeutics: An Assessment On A Lottery Ticket
Oct 21Aileron Therapeutics: Solving Chemotherapy's Toxicity
May 01Aileron Therapeutics +31% on insider buying more shares
Jan 08Aileron raises $40M via equity offering
Jan 06Aileron Therapeutics EPS in-line
Nov 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$29m |
| Jun 30 2024 | n/a | n/a | -US$25m |
| Mar 31 2024 | n/a | n/a | -US$18m |
| Dec 31 2023 | US$716k | US$85k | -US$16m |
Compensation vs Market: James's total compensation ($USD715.92K) is about average for companies of similar size in the US market ($USD645.47K).
Compensation vs Earnings: Insufficient data to compare James's compensation with company performance.
CEO
James Windsor (58 yo)
1.3yrs
Tenure
US$715,921
Compensation
Dr. James Brian Windsor, Ph.D. is Chief Executive Officer and Director of Aileron Therapeutics, Inc. from March 11, 2024 and its President. Dr. Windsor served as Chief Operating Officer and President from...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$715.92k | 0.036% $ 16.3k | |
| Independent Chairman | 5.6yrs | US$67.97k | 0.10% $ 47.0k | |
| Independent Director | 1.3yrs | US$15.64k | 0% $ 0 | |
| Member of Scientific Advisory Board | 6.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.8yrs | no data | no data | |
| Independent Lead Director | 11.6yrs | US$46.25k | 0.0013% $ 612.6 | |
| Independent Director | 1.3yrs | US$9.38k | 0% $ 0 | |
| Director | 6.3yrs | US$630.74k | 0.00023% $ 105.1 | |
| Member of Scientific Advisory Board | no data | no data | no data |
6.3yrs
Average Tenure
65.5yo
Average Age
Experienced Board: ALRN's board of directors are considered experienced (6.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/12 03:58 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aileron Therapeutics, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ying Huang | BofA Global Research |
| Brian Kemp Dolliver | Brookline Capital Markets |
| John Newman | Canaccord Genuity |